Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
Preprint
Abstract
SUMMARY: Vaccination elicits immune responses capable of potently neutralizing SARS-CoV-2. However, ongoing surveillance has revealed the emergence of variants harboring mutations in spike, the main target of neutralizing antibodies. To understand the impact of these variants, we evaluated the neutralization potency of 99 individuals that received one or two doses of either BNT162b2 or mRNA-1273 vaccines against pseudoviruses representing 10 globally circulating strains of SARS-CoV-2. Five of the 10 pseudoviruses, harboring receptor-binding domain mutations, including K417N/T, E484K, and N501Y, were highly resistant to neutralization. Cross-neutralization of B.1.351 variants was comparable to SARS-CoV and bat-derived WIV1-CoV, suggesting that a relatively small number of mutations can mediate potent escape from vaccine responses. While the clinical impact of neutralization resistance remains uncertain, these results highlight the potential for variants to escape from neutralizing humoral immunity and emphasize the need to develop broadly protective interventions against the evolving pandemic.Keywords
All Related Versions
- Published version: Cell, 184 (9), 2523.
This publication has 46 references indexed in Scilit:
- A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severityCellular & Molecular Immunology, 2021
- COVID-19-neutralizing antibodies predict disease severity and survivalCell, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineNew England Journal of Medicine, 2020
- Development and effectiveness of pseudotyped SARS-CoV-2 system as determined by neutralizing efficiency and entry inhibition test in vitroBiosafety and Health, 2020
- Spike mutation D614G alters SARS-CoV-2 fitnessNature, 2020
- Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein VariantCell, 2020
- Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 VirusCell, 2020
- SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controlsNature, 2020
- A human monoclonal antibody blocking SARS-CoV-2 infectionNature Communications, 2020
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease InhibitorCell, 2020